.com is pleased to announce a new with , CEO of Soligenix, Inc. (:)


 

Soligenix - SNGX

Soligenix, Inc. is a late stage company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Financial Reporting/Disclosure
Reporting StatusU.S. Reporting: SEC Reporting
Audited FinancialsAudited
Latest ReportJun 30, 2015 10-Q
CIK0000812796
Fiscal Year End12/31
MarketplaceOTCQB
Profile Data
SIC – Industry Classification2834 – Pharmaceutical preparations
Business StatusDevelopment Stage Company a/o Jun 10, 2013
Incorporated In:DE, USA
Year of Inc.Not Available
EmployeesNot Available
Company Officers/Contacts
Christopher J. SchaberPresident, CEO
Richard StraubeSenior VP, Chief Med. Officer
Oreola DoniniSenior VP, Chief Scientific Officer
Joseph M. WaruszVice President, Acting CFO, Principal Acct. Officer
Company Directors
Christopher J. SchaberChairman
Keith Brownlie
Marco Brughera
Gregg Lapointe
Robert Rubin
Jerry Zeldis
Company Notes
  • Formerly=DOR BioPharma, Inc. until 9-2009
  • Formerly=Endorex Corp. until 12-01
  • Formerly=ImmunoTherapeutics, Inc. until 9-96
Service Providers

Accounting/Auditing Firm

EisnerAmper LLP
101 West Avenue
P.O. Box 458
Jenkintown, PA, 19046
United States

Tags